A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100039
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Novartis Investigative Site
-
-
Shanxi
-
Xi'an, Shanxi, China, 710032
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Novartis Investigative Site
-
-
-
-
-
Hong Kong, Hong Kong
- Novartis Investigative Site
-
Shatin, New Territories, Hong Kong
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama-city, Kanagawa, Japan, 232-0024
- Novartis Investigative Site
-
-
Osaka
-
OsakaSayama, Osaka, Japan, 589-8511
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 136-705
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 05505
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 06351
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 110 744
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 03722
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
-
Taichung, Taiwan, 40705
- Novartis Investigative Site
-
Taipei, Taiwan, 10048
- Novartis Investigative Site
-
-
Taiwan, ROC
-
Taipei, Taiwan, ROC, Taiwan, 112
- Novartis Investigative Site
-
-
Taoyuan/ Taiwan ROC
-
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Novartis Investigative Site
-
Khon Kaen, Thailand, 40002
- Novartis Investigative Site
-
Songkla, Thailand, 90110
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of advanced Hepatocellular Carcinoma (HCC) according to the AASLD Guidelines
- Advance HCC Stage B and C according to BCLC staging classification
- Child Pugh A
- At least one measurable lesion as assessed by CT or MRI
- ECOG PS of 0 or 1
- Adequate bone marrow, liver, and renal function
Exclusion Criteria:
- Prior systemic therapy for HCC
- Brain metastases
- Active bleeding (including variceal bleeding as the result of esophageal varices) Patients who have received a liver transplant or are awaiting an immediate transplant
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TKI258
capsule
|
500 mg p.o. o.d. 5 days on/2 days off
Other Names:
|
|
Experimental: Sorafenib
tablet
|
400 mg p.o. b.i.d.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival - Overall Survival
Time Frame: Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
The overall survival (OS), defined as the time from date of randomization to the date of death from any cause.
If a patient was not known to have died at the date of analysis cut-off, OS was censored at the last date of contact.
Survival information was collected every 6 wks until at least 130 deaths have been observed
|
Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Tumor Progression (Tumor Assessment)
Time Frame: Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1).
For target lesions, disease progression mean at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
For non-target lesions, disease progression refers to unequivocal progression of existing non-target lesions.
In addition, the appearance of new lesions is always considered as disease progression.
|
Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
|
Disease Control Rate (Tumor Assessment)
Time Frame: Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
Disease Control Rate (DCR) is defined as the proportion of patients whose best overall response is either complete response [CR], partial response [PR] or stable disease [SD] according to RECIST 1.1.
|
Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first.
|
|
Time to Definitive Deterioration in ECOG Performance Status (PS)
Time Frame: Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first
|
Time to definitive deterioration on ECOG PS scale (by at least one point) was defined as the time from the date of randomization to the date of definitive deterioration of the ECOG PS by at least one category of the score from baseline or to the date of death whichever occurred earlier.
0 is Fully active, able to carry on all pre-disease performance without restriction, 1 is Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g.
light housework, office work and 2 is ambulatory and capable of all self-care but unable to carry out any work activities.
Up and about more than 50% of waking hours.
|
Every 6 weeks from date of randomization until the patient has progressed, or the patient can no longer be followed, or at least 130 deaths have been observed in the study, whichever came first
|
|
Pharmacokinetic (PK) Parameter of Cmax Following a Single Dose of TKI258
Time Frame: Week 1 day 1, week 4 day 5
|
Cmax will be evaluated after a single dose of TKI258 following a 5 days on/2 days off dosing schedule.
Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after a single dose administration (mass x volume - 1).
|
Week 1 day 1, week 4 day 5
|
|
Pharmacokinetic (PK) Parameter of Tmax Following a Single Dose of TKI258
Time Frame: Week 1 day 1, week 4 day 5
|
Tmax will be evaluated after a single dose of TKI258 following a 5 days on/2 days off dosing schedule.
Tmax is the time to to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after a single dose administration (time)
|
Week 1 day 1, week 4 day 5
|
|
Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258
Time Frame: Week 1 day 1, week 4 day 5
|
The mean AUC from time zero to the last measurable concentration sampling time (t last) (mass x time x volume-1)
|
Week 1 day 1, week 4 day 5
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
Other Study ID Numbers
Other Study ID Numbers
- CTKI258A2208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.